BioVie Inc. Amortization of Debt Issuance Costs
BioVie Inc. (BIVI) reported Amortization of Debt Issuance Costs of $12.00 thousand for the 12-month period ending 2025-06-30, per its S-1/A filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-06
- BioVie Inc. amortization of debt issuance costs for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- BioVie Inc. amortization of debt issuance costs for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- BioVie Inc. amortization of debt issuance costs for the quarter ending 2024-12-31 was $2.00K, a 93.55% decline year-over-year.
- BioVie Inc. amortization of debt issuance costs for the quarter ending 2024-09-30 was $9.50K, a 75.00% decline year-over-year.
- BioVie Inc. amortization of debt issuance costs for fiscal 2023 was $170.00M, a 171617.17% increase from fiscal 2022.
- BioVie Inc. amortization of debt issuance costs for fiscal 2022 was $99.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month | Amortization of Debt Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $2.00K derived: sum of 3 quarters · filed 2026-08-06 | $12.00K S-1/A · filed 2026-08-06 | |
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $2.00K derived: sum of 2 quarters · filed 2025-05-12 | $12.00K 10-Q · filed 2025-05-12 | $28.50K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-12-31 | $2.00K 10-Q · filed 2025-02-11 | $12.00K 10-Q · filed 2025-02-11 | $28.50K derived: sum of 3 quarters · filed 2026-08-06 | $52.50K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-09-30 | $9.50K 10-Q · filed 2024-11-13 | $26.50K derived: sum of 2 quarters · filed 2026-08-06 | $50.50K derived: sum of 3 quarters · filed 2026-08-06 | $81.50K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-06-30 | $17.00K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-06 | $41.00K derived: sum of 2 quarters · filed 2026-08-06 | $72.00K derived: sum of 3 quarters · filed 2026-08-06 | $109.00K S-1/A · filed 2026-08-06 | $109.00M 10-K · filed 2024-09-30 |
| 2024-03-31 | $24.00K 10-Q · filed 2025-05-12 | $55.00K derived: sum of 2 quarters · filed 2025-05-12 | $92.00K 10-Q · filed 2025-05-12 | $169.97M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $31.00K 10-Q · filed 2025-02-11 | $69.00K 10-Q · filed 2025-02-11 | $169.94M derived: sum of 3 quarters · filed 2025-02-11 | $169.98M derived: sum of 4 quarters · filed 2025-02-11 | |
| 2023-09-30 | $38.00K 10-Q · filed 2024-11-13 | $169.91M derived: sum of 2 quarters · filed 2024-11-13 | $169.95M derived: sum of 3 quarters · filed 2024-11-13 | $170.00M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $169.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $169.91M derived: sum of 2 quarters · filed 2024-09-30 | $169.96M derived: sum of 3 quarters · filed 2024-09-30 | $170.00M 10-K · filed 2024-09-30 | $170.00K 10-K · filed 2023-08-16 |
| 2023-03-31 | $43.00K 10-Q · filed 2024-05-14 | $86.00K derived: sum of 2 quarters · filed 2024-05-14 | $128.00K 10-Q · filed 2024-05-14 | $171.00K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $43.00K 10-Q · filed 2024-02-13 | $85.00K 10-Q · filed 2024-02-13 | $128.00K derived: sum of 3 quarters · filed 2024-02-13 | $171.00K derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-09-30 | $43.00K 10-Q · filed 2023-11-08 | $85.00K derived: sum of 2 quarters · filed 2023-11-08 | $128.00K derived: sum of 3 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-16 | $85.00K derived: sum of 2 quarters · filed 2023-08-16 | $99.00K 10-K · filed 2023-08-16 | ||
| 2022-03-31 | $43.00K 10-Q · filed 2023-05-12 | $57.00K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |